MYX mayne pharma group limited

Mayne Pharma has an extensive women’s health portfolio focused on contraceptives., page-3

  1. 1,066 Posts.
    lightbulb Created with Sketch. 92
    What will Mayne Pharma be selling?
    Mayne Pharma picks up the licence for the following products:
    BIJUVA - A menopause treatment to treat hot flushes (licence until 2032)
    IMVEXXY - Another menopause treatment used to treat vaginal pain (licence until 2034)ANNOVERA - A long-term self-insertable contraceptive product (licence until 2039)BocaGreenMD - Prenatal vitamins emphasising natural ingredients VitaMedMD - Prenatal vitamins
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$5.08
Change
0.010(0.20%)
Mkt cap ! $412.7M
Open High Low Value Volume
$5.05 $5.08 $5.02 $395.8K 78.38K

Buyers (Bids)

No. Vol. Price($)
1 1996 $5.05
 

Sellers (Offers)

Price($) Vol. No.
$5.08 3084 3
View Market Depth
Last trade - 16.10pm 07/08/2025 (20 minute delay) ?
MYX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.